| Literature DB >> 19231647 |
Jenny E Murase1, Jashin J Wu, Ivan Theate, Gary W Cole, Ronald J Barr, Senait W Dyson.
Abstract
Bortezomib, a proteasome inhibitor approved for the treatment of multiple myeloma, has been reported to be associated with Sweet syndrome. However, careful review of the histopathology of the first reported case and our case revealed similar histologic and immunohistochemical findings (a mononuclear dermal infiltrate) and not the usual neutrophilic infiltrate of Sweet syndrome. We suggest that the dermatitis induced by bortezomib is best classified as "histiocytoid Sweet syndrome."Entities:
Mesh:
Substances:
Year: 2009 PMID: 19231647 DOI: 10.1016/j.jaad.2008.09.007
Source DB: PubMed Journal: J Am Acad Dermatol ISSN: 0190-9622 Impact factor: 11.527